Phase III Randomized, double blind, placebo controlled trial of adjunctive Troriluzole in Obsessive Compulsive Disorder.
Troriluzole is a glutamate modulating drug that is being developed for potential treatment of OCD as adjunctive therapy to standard of care treatments in subjects who have experienced an inadequate response to current pharmacotherapy.
Criteria:Male and Female ages 18-65
Diagnosis of OCD greater than 1 year
Subjects must be currently experiencing non-response or inadequate response to their current standard of care medication.
Must currently be on an SSRI for at least 8 weeks.